Thursday 25 Jul, 2024 11:15 AM
Site map | Locate Us | Login
   Craftsman Automation edges lower after weak Q1 performance    L&T gains as Q1 PAT rises 12% YoY to Rs 2,786 cr    Axis Bank drops as Q1 asset quality deteriorates    FMCG shares gain    Industrials shares rise    Capital Goods stocks edge higher    RVNL gets acceptance letter from South Eastern Railway for Rs 191 crore project    Jindal Steel & Power Ltd Slips 4.53%, BSE Metal index Shed 1.65%    Suzlon Energy Ltd Spikes 4.88%    Dish TV India board OKs raising Rs 1,000 crore    Axis Bank PAT rises 4% YoY to Rs 6,035 crore in Q1 FY25    L&T Q1 PAT rises 12% YoY to Rs 2,786 cr    NSE SME SAR Televenture's FPO ends with 7.46 times subscription    Epigral hits 52-week high after Q1 PAT soars YoY to Rs 86 cr    Tips Inds hits 52-week high after Q1 PAT rises 61% YoY to Rs 44 cr 
Saravan Stocks
Hot Pursuit
Scrips, which has significant changes during the market hours.
Sun Pharma gains on reporting turnaround Q4 performance
26-May-23   15:57 Hrs IST

Net sales jumped 15.71% to Rs 10930.6 crore in Q4 FY23 as against Rs 9446.7 crore recorded in Q4 FY22.

Sales of formulations in India for Q4 FY23 were at Rs 3,364.1 crore, up 8.7% over Q4 last year. India formulation sales accounted for about 31% of total consolidated sales.

US formulation sales were $ 430 million for Q4 FY23, a growth of 10.5% over Q4 last year and accounted for about 33% of total consolidated sales for the quarter

Taro posted Q4FY23 sales of $147 million, up by 2.3% YoY and net profit of about US$ 6.9 million, lower by 74.7% over adjusted net profit of Q4 last year.

Formulation sales in Emerging Markets sales were $ 221 million for Q4 FY23, a growth of 7.5% over Q4 last year and accounted for about 17% of total consolidated sales for the quarter.

Formulation sales rest of the world (RoW) market sales were $191 million for Q4FY23, a growth of 7.4% over Q4 last year and accounted for approximately 14.7% of total consolidated sales for the quarter.

For Q4 FY23, external sales of API were at Rs 385.2 crore for Q4FY23, lower by about 6.9% over Q4 last year. The company's API business imparts benefits of vertical integration and continuity of supply chain for its formulations business.

Consolidated R&D investment for Q4FY23 was at Rs 665.66 crore as compared to Rs 543.29 crore for Q3 last year.

EBITDA was at Rs 2,802.1 crore, up 19.7% YoY. EBITDA margin for Q4 at 25.6% as against 24.8% for Q3 last year.

On full year basis, the company's consolidated net profit of Rs surged 179.93% to Rs 10,503.4 crore in FY23 as compared with Rs 3752.1 crore in FY22. Net sales jumped 13.53% year on year to Rs 43,885.6 crore in FY23.

Dilip Shanghvi, managing director of the company, said, ?I am pleased with well-rounded growth demonstrated in FY23 by the company. Several of our businesses including Specialty, India and Emerging markets have continued to progress well. Our Specialty business remains on growth path and we are committed to continue scaling it up. Acquisition of Concert helps further strengthen our portfolio in dermatology. I believe deuruxolitinib can become a leading product to address highly unmet need in alopecia areata patients.?

Meanwhile, the board has recommended a dividend of Rs 4 per equity share for FY23, subject to approval of shareholders.

Sun Pharmaceuticals Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID:       Customers grievances :     Compliance officer : Mr.R Udayakumar ,,  Mobile No: 7305522205
Hit Count : 34155519
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd